- Trials with a EudraCT protocol (47)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
47 result(s) found for: Chemical state.
Displaying page 1 of 3.
EudraCT Number: 2007-001784-30 | Sponsor Protocol Number: STIPOP - STP167 | Start Date*: 2007-07-19 |
Sponsor Name:BIOCODEX | ||
Full Title: Population pharmacokinetic study in Dravet's syndrome patients treated with stiripentol, valproate and clobazam. Open pharmacokinetic multicenter study. | ||
Medical condition: Antiepileptic | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001966-40 | Sponsor Protocol Number: CD001 | Start Date*: 2014-01-27 | ||||||||||||||||
Sponsor Name:Companion Diagnostics BV | ||||||||||||||||||
Full Title: A double blind, randomized, placebo controlled, cross-over, Lybridos dose finding study to validate the predictive power of the diagnostic model for Lybrido and Lybridos efficacy and to identify an... | ||||||||||||||||||
Medical condition: Hypoactive Sexual Desire Disorder/SSRI-induced sexual dysfunction | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000615-99 | Sponsor Protocol Number: 00465 | Start Date*: 2006-12-28 | |||||||||||
Sponsor Name:University Medical Center Freiburg | |||||||||||||
Full Title: Freiburger ZNS-NHL Studie Therapie für Patienten mit primären Non-Hodgkin Lymphomen des ZNS – Sequentielle Hochdosis-Chemotherapie mit autologer peripherer Blutstammzelltransplantation | |||||||||||||
Medical condition: primary Non-Hodgkin Lymphoma of the Central Nervous System (PCNSL), histologically confirmed Age: 18 - 65 years | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001472-12 | Sponsor Protocol Number: A7501009 Amendment 1 | Start Date*: 2006-04-12 | |||||||||||
Sponsor Name:N V Organon | |||||||||||||
Full Title: A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing Trial A7501008 and Continuing Lithium or Valproic Acid/Divalp... | |||||||||||||
Medical condition: Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023508-28 | Sponsor Protocol Number: CAMN107GB05T | Start Date*: 2011-04-14 |
Sponsor Name:Plymouth Hospital NHS Trust | ||
Full Title: A CLINICAL TRIAL OF THE INTRA-TUMOURAL CONCENTRATION AND ACTIVITY OF NILOTINIB IN INTRA-CUTANEOUS SCHWANNOMAS | ||
Medical condition: In vivo investigation of the intra-tumoural concentration and activity of nilotinib in cutaneous schwannomas (CS) in patienst with Neurofibromatosis 2 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-002169-35 | Sponsor Protocol Number: 25544 | Start Date*: 2005-12-27 | |||||||||||
Sponsor Name:NV Organon | |||||||||||||
Full Title: A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the safety and Efficacy of Asenapine With Olanzapine in Subjects who Completed Protocol 25543 | |||||||||||||
Medical condition: Schizophrenia with predominant, persistent negative symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) ES (Completed) CZ (Completed) DE (Completed) HU (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002462-32 | Sponsor Protocol Number: SHW01 | Start Date*: 2022-12-09 | |||||||||||
Sponsor Name:Suchthilfe Wien gGmbH | |||||||||||||
Full Title: Pilot study on the safety and feasibility of intravenous opioid agonist therapy (OAT) with Hydagelan® (hydromorphone hydrochloride) in Vienna. | |||||||||||||
Medical condition: Opioid dependence: Opioid dependence is a serious and usually chronic disease that requires treatment, encompasses various psychological and physical dimensions, and is associated with concomitant ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004450-24 | Sponsor Protocol Number: PHIX-IT | Start Date*: 2019-08-01 |
Sponsor Name:Tergooi Hospital, dep of internal medicine | ||
Full Title: A pharmacokinetic study of edoxaban in patients with breast cancer using the P-glycoprotein inhibitor tamoxifen | ||
Medical condition: If there are increased plasma levels of edoxaban when used concomitantly with the P-glycoproteïne inhibitor tamoxifen for the treatment of venous thromboembolism in patients with breast cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004447-11 | Sponsor Protocol Number: VR040/2/008 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Vectura Limited | |||||||||||||
Full Title: A Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With “On-Off” or “Wearing-Off” Effe... | |||||||||||||
Medical condition: Unpredictable motor fluctuation or “On-Off” or “Wearing-Off” Effects Fluctuating associated with Idiopathic Parkinson’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006673-91 | Sponsor Protocol Number: RD.03.SPR.40051 | Start Date*: 2008-07-04 | |||||||||||
Sponsor Name:GALDERMA R&D SNC | |||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CD5024 1% CREAM TREATMENT FOR UP TO 52 WEEKS IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA | |||||||||||||
Medical condition: PATIENTS WITH PAPULOPUSTULAR ROSACEA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Prematurely Ended) HU (Completed) IS (Prematurely Ended) CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002560-17 | Sponsor Protocol Number: 25543 | Start Date*: 2005-04-14 | |||||||||||
Sponsor Name:NV Organon | |||||||||||||
Full Title: A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizop... | |||||||||||||
Medical condition: Schizophrenia with predominant, persistent negative symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DK (Prematurely Ended) SE (Completed) DE (Completed) CZ (Completed) GB (Completed) IT (Completed) ES (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000978-68 | Sponsor Protocol Number: | Start Date*: 2006-12-18 |
Sponsor Name:AstraZeneca | ||
Full Title: Treatment of systemic effects in patients with COPD | ||
Medical condition: Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease state characterized by airflow limitation that is not fully reverible. The airflow limitation is usually progress... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004480-39 | Sponsor Protocol Number: DPP4-Hypo | Start Date*: 2017-12-22 | |||||||||||
Sponsor Name:Profil Institut für Stoffwechselforschung GmbH | |||||||||||||
Full Title: DPP-4 inhibition with sitagliptin and the risk for hypoglycaemia in the fasting state in subjects with type 2 diabetes treated to fasting plasma glucose targets with insulin glargine and metformin | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001960-31 | Sponsor Protocol Number: S54348 | Start Date*: 2013-05-03 |
Sponsor Name:UZ Leuven | ||
Full Title: Combined drug Approach to Prevent Ischemia-reperfusion injury during Transplantation of Livers (CAPITL): a first-in-men study | ||
Medical condition: Investigation of the ischemia-reperfusion injury in patients who will undergo a liver transplantation after receiving a drug combination/multifactorial modulation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000470-78 | Sponsor Protocol Number: TRA102537 | Start Date*: 2006-10-30 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administe... | |||||||||||||
Medical condition: Idiopathic thrombocytopenic purpura (ITP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FI (Completed) DK (Completed) FR (Completed) AT (Completed) CZ (Completed) SK (Completed) DE (Completed) GR (Completed) IT (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002880-86 | Sponsor Protocol Number: 936 | Start Date*: 2013-01-25 | |||||||||||
Sponsor Name:Liverpool Heart and Chest Hospital NHS Trust | |||||||||||||
Full Title: PRESERVING ΒETA-CELLS: ‘RESTING THE PANCREAS’ IN CYSTIC FIBROSIS | |||||||||||||
Medical condition: Cystic Fibrosis Related Diabetes (CFRD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003080-31 | Sponsor Protocol Number: 172003 | Start Date*: 2006-12-12 | |||||||||||
Sponsor Name:NV Organon | |||||||||||||
Full Title: A multi-center, double-blind, flexible-dose efficacy trial with Org 25935 versus placebo as add-on therapy in subjects with predominant, persistent negative symptoms of schizophrenia treated with a... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) FI (Completed) FR (Completed) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001336-22 | Sponsor Protocol Number: AX-PC-201 | Start Date*: 2004-11-03 |
Sponsor Name:Axonyx Inc. | ||
Full Title: Effect of Phenserine Treatment on Amyloid in Brains of Patients with Mild Probable Alzheimer’s Disease as studied by Positron Emission Tomography (PET). A Randomised, three Months Double-Blind, Pla... | ||
Medical condition: Alzheimer’s Disease (AD) is the most common disease leading to dementia and it affects approximately 4 to 8% of the population aged above 65 years. The disease incidence is closely correlated with ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002330-13 | Sponsor Protocol Number: COAM-CFD-01 | Start Date*: 2022-06-22 | |||||||||||
Sponsor Name:Fakultní nemocnice v Motole | |||||||||||||
Full Title: The randomized, double blind study phase III.b of the Comprehensive assessment of the musculoskeletal health in children with cystic fibrosis – on the search for means of improvement | |||||||||||||
Medical condition: musculoskeletal health in children with cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001438-25 | Sponsor Protocol Number: VWM1 | Start Date*: 2020-04-21 |
Sponsor Name:VU University Medical Center | ||
Full Title: A Study to Explore the Safety, Tolerability, Pharmacokinetic Profile, and Potential Efficacy of Guanabenz in Patients With Early Childhood Onset Vanishing White Matter (VWM) | ||
Medical condition: Vanishing white matter | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
